Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications

Animal models of Alzheimer’s disease amyloidosis that recapitulate cerebral amyloid-beta pathology have been widely used in preclinical research and have greatly enabled the mechanistic understanding of Alzheimer’s disease and the development of therapeutics. Comprehensive deep phenotyping of the pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ruiqing Ni
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Alzheimer’s disease amyloid-beta animal model astrocyte blood–brain barrier imaging Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/b94e0aa7e39d4902b25977fc04b4c41e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b94e0aa7e39d4902b25977fc04b4c41e
record_format	dspace
spelling	oai:doaj.org-article:b94e0aa7e39d4902b25977fc04b4c41e2021-11-25T18:39:57ZPositron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications10.3390/ph141111791424-8247https://doaj.org/article/b94e0aa7e39d4902b25977fc04b4c41e2021-11-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1179https://doaj.org/toc/1424-8247Animal models of Alzheimer’s disease amyloidosis that recapitulate cerebral amyloid-beta pathology have been widely used in preclinical research and have greatly enabled the mechanistic understanding of Alzheimer’s disease and the development of therapeutics. Comprehensive deep phenotyping of the pathophysiological and biochemical features in these animal models is essential. Recent advances in positron emission tomography have allowed the non-invasive visualization of the alterations in the brain of animal models and in patients with Alzheimer’s disease. These tools have facilitated our understanding of disease mechanisms and provided longitudinal monitoring of treatment effects in animal models of Alzheimer’s disease amyloidosis. In this review, we focus on recent positron emission tomography studies of cerebral amyloid-beta accumulation, hypoglucose metabolism, synaptic and neurotransmitter receptor deficits (cholinergic and glutamatergic system), blood–brain barrier impairment, and neuroinflammation (microgliosis and astrocytosis) in animal models of Alzheimer’s disease amyloidosis. We further propose the emerging targets and tracers for reflecting the pathophysiological changes and discuss outstanding challenges in disease animal models and future outlook in the on-chip characterization of imaging biomarkers towards clinical translation.Ruiqing NiMDPI AGarticleAlzheimer’s diseaseamyloid-betaanimal modelastrocyteblood–brain barrierimagingMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1179, p 1179 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Alzheimer’s disease amyloid-beta animal model astrocyte blood–brain barrier imaging Medicine R Pharmacy and materia medica RS1-441
spellingShingle	Alzheimer’s disease amyloid-beta animal model astrocyte blood–brain barrier imaging Medicine R Pharmacy and materia medica RS1-441 Ruiqing Ni Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
description	Animal models of Alzheimer’s disease amyloidosis that recapitulate cerebral amyloid-beta pathology have been widely used in preclinical research and have greatly enabled the mechanistic understanding of Alzheimer’s disease and the development of therapeutics. Comprehensive deep phenotyping of the pathophysiological and biochemical features in these animal models is essential. Recent advances in positron emission tomography have allowed the non-invasive visualization of the alterations in the brain of animal models and in patients with Alzheimer’s disease. These tools have facilitated our understanding of disease mechanisms and provided longitudinal monitoring of treatment effects in animal models of Alzheimer’s disease amyloidosis. In this review, we focus on recent positron emission tomography studies of cerebral amyloid-beta accumulation, hypoglucose metabolism, synaptic and neurotransmitter receptor deficits (cholinergic and glutamatergic system), blood–brain barrier impairment, and neuroinflammation (microgliosis and astrocytosis) in animal models of Alzheimer’s disease amyloidosis. We further propose the emerging targets and tracers for reflecting the pathophysiological changes and discuss outstanding challenges in disease animal models and future outlook in the on-chip characterization of imaging biomarkers towards clinical translation.
format	article
author	Ruiqing Ni
author_facet	Ruiqing Ni
author_sort	Ruiqing Ni
title	Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
title_short	Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
title_full	Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
title_fullStr	Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
title_full_unstemmed	Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
title_sort	positron emission tomography in animal models of alzheimer’s disease amyloidosis: translational implications
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b94e0aa7e39d4902b25977fc04b4c41e
work_keys_str_mv	AT ruiqingni positronemissiontomographyinanimalmodelsofalzheimersdiseaseamyloidosistranslationalimplications
_version_	1718410859887198208

Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications

Ejemplares similares